ELMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Electromed (ELMD) is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The business looks fundamentally healthy and analysts remain positive, but the stock is already extended technically and there is no fresh catalyst from news or insider activity. Since the user is impatient and wants a direct answer, my opinion is to wait rather than buy at this level.
ELMD is in a strong uptrend: MACD histogram is positive and expanding, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. However, RSI_6 is 94.09, which is extremely overbought and suggests the move has run too far too fast. Price at 46.34 is above the first resistance at 44.48 and near the second resistance at 46.82, making the current entry less attractive despite the bullish trend.
No news in the last week, so there is no immediate event-driven catalyst. The main positives are: continued strength in homecare and a hospital rebound, 18.4% revenue growth in the latest reported quarter, strong operating leverage, expanding payer coverage, and a large underpenetrated bronchiectasis market. Analyst sentiment remains constructive with a Buy rating reaffirmed and price target raised to $40.
There has been no recent news flow, no significant hedge fund or insider buying, and no recent congress trading data. The stock’s RSI is extremely overbought, which reduces near-term entry quality. Also, the share price is already above the latest analyst price target of $40, suggesting limited upside from current levels based on that estimate.
Latest quarter shown: Q3. Electromed posted record Q3 results with 18.4% revenue growth and strong operating leverage. Growth was driven by strength in homecare and a rebound in hospital activity. Management also noted some one-time tailwinds, but the overall trend remains one of sustained double-digit growth supported by adoption and payer expansion.
Recent analyst trend is positive. On 2026-05-13, B. Riley raised its price target on Electromed to $40 from $38 and kept a Buy rating. The pros view is that ELMD is executing well with strong revenue growth, improving operating leverage, and a long runway in an underpenetrated market. The cons view is that the stock may already be priced ahead of fundamentals since it trades above the updated target, limiting near-term upside.
